Clinical Trials in Chicago

Showing 8081-8100 of 20,493 trials

Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)

NCT06170268

The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed to grow with scientific and medical advancements. As new treatments are approved and implemented in care, ALZ-NET will track the long-term health outcomes associated with their use in a real-world setting. ALZ-NET is a resource for evidence gathering, information sharing and education across clinical and research communities, encouraging innovative research and supporting opportunities to improve clinical care delivery. All participating physicians and site staff will complete comprehensive training to ensure adherence of data requirements and registry timelines.

Alzheimer Disease

Alzheimer's Disease and Related Disorders Association, Inc20,000 participantsStarted Oct 2022

Chicago, Illinois, United States

COMPLETEDPhase 22.2 miles

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

NCT01624285

The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation

Adult Primary Hepatocellular CarcinomaLocalized Resectable Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer+1 more

Jonsson Comprehensive Cancer Center20 participantsStarted Jul 2012

Birmingham, Alabama, United States • Los Angeles, California, United States • Denver, Colorado, United States +18 more locations

Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Find Trials by Condition in Chicago

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)

Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit

Intranasal Oxytocin for Frontotemporal Dementia

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

The Canadian/US Integrative Oncology Study

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

iCanCope With Sickle Cell Pain

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia